Skip to content
OpenCapital
Get started

Syndax Pharmaceuticals SNDX Increase Decrease In Collaboration Receivable

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K—
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.77B+95.0%
Enterprise value$1.99B+84.0%
P/S8.1×-12.6×

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept sndx:IncreaseDecreaseInCollaborationReceivable.

The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Syndax Pharmaceuticals's increase decrease in collaboration receivable.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Syndax Pharmaceuticals's increase decrease in collaboration receivable?
Syndax Pharmaceuticals (SNDX) reported increase decrease in collaboration receivable of $3.24M in Q1 2026.
How has Syndax Pharmaceuticals's increase decrease in collaboration receivable changed year-over-year?
Syndax Pharmaceuticals's increase decrease in collaboration receivable increased by 146.0% year-over-year, from -$7.04M to $3.24M.